Friday, August 7, 2009

Alnylam’s net loss widens in Q2

By Julie M. Donnelly

Video Gallery

MHT's Efrain Viscarolasaga: Tech companies may have to wait for stimulus funds

MHT's Marc Songini: Researchers focus on macular degeneration

MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban

Related News

Regulus lands $20M in Series A round [March 4, 2009]

Inside Fast Growth Technology Companies: Fast-growth firms see stock plummet by end of 2008 [January 16, 2009]

Alnylam could get $102M from Cubist RNAi development deal [January 9, 2009]

Alnylam, Brightcove, Phase Forward named ‘Tech Pioneers’ [December 4, 2008]

Alnylam wins $20M payment from partner Takeda [October 7, 2008]

Alnylam Pharmaceuticals is reporting a widening loss due to the company’s burgeoning portfolio of partnerships and increased research and development costs.

The Cambridge-based biotechnology company focusing on RNA interference technologies, had a net loss of $22.7 million in the second quarter of 2009, up from $12.8 million during the corresponding period in 2008.

Research and development costs increased to $38.6 million for the second quarter of 2009 up from $29.6 million for the second quarter of last year. The company reports that the increase in research and development spending was due to increased costs for clinical and pre-clinical program and licence payments the company made in conjunction with a collaboration with Isis Pharmaceuticals.

Alnylam had cash on hand of $473.8 million on June 30, down from $512.7 million at the end of 2008.

Alnylam has been granted 30 patents since the beginning of the year — double the amount the company predicted for the year.

Alnylam’s (Nasdaq:ALNY) stock was trading at $21.58 in midday trading on Friday, up from $22.21 at the previous close.